Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity TA1152 7 May 2026 7 May 2026 Zanidatamab for treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results